Characteristics | Overall |
---|---|
 | N = 517 |
Sex (female) | 429 (83.0) |
Age, years | 62.5 (61.4–63.6) |
Disease duration, months | 160.9 (148.8–173.1) |
Stage | Â |
I | 114 (22.1) |
II | 125 (24.2) |
III | 96 (18.6) |
IV | 180 (35.0) |
Disease activity | Â |
DAS28-CRP | 1.91 (1.83–1.98) |
DAS28-CRP remission†| 360 (78.9) |
Low disease activity†| 57 (12.5) |
Moderate disease activity†| 37 (8.1) |
High disease activity†| 2 (0.5) |
TJC | 0.82 (0.69–0.96) |
SJC | 0.80 (0.67–0.93) |
PtGA | 29.1 (27.0–31.2) |
CRP | 0.40 (0.33–0.47) |
HAQ-DI | 0.75 (0.68–0.82) |
HAQ-DI remission | 252 (51.3) |
Pain VAS | 27.6 (25.4–29.9) |
Treatment | Â |
Biological DMARD | 187 (36.2) |
Methotrexate | 345 (66.7) |
Steroid | 159 (30.8) |
Anxiety and depression | Â |
Anxiety | 91 (17.6) |
Depression | 143 (27.7) |